Current views on reactions in leprosy

Indian Journal of Leprosy

Volumn 72, Issue 1, 2000, Pages 97-122

  Naafs, B ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CHLOROQUINE; CHLORPROMAZINE; CLOFAZIMINE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN A; DAPSONE; HISTAMINE; IMMUNOGLOBULIN; INTERLEUKIN 2; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PREDNISOLONE; PREDNISONE; PROMETHAZINE; PROSTAGLANDIN INHIBITOR; RIFAMPICIN; STIBOPHEN; SULFONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; CELLULAR IMMUNITY; CHEMOTHERAPY; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; ERYTHEMA NODOSUM LEPROSUM; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LEPROMATOUS LEPROSY; LEPROSY; LEUKOCYTOSIS; LUCIO PHENOMENON; NERVE INJURY; NEUROPATHY; ORCHITIS; PYREXIA IDIOPATHICA; REVERSAL REACTION; SKIN EDEMA; SKIN MANIFESTATION;

ERYTHEMA NODOSUM; HUMANS; LEPROSY, BORDERLINE; LEPROSY, LEPROMATOUS; NERVE DEGENERATION; PERIPHERAL NERVES;

EID: 0033871601     PISSN: 02549395     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (122)

1. Surgical management of leprous neuritis
2. Pharmacological manipulation of the complement system
3. Studies on T-cell subsets and functions in leprosy
4. Tumor necrosis factor production in patients with leprosy
5. Antigenic heterogeneity in patients with reactions in borderline leprosy
6. Evidence for prevention of borderline leprosy reactions by dapsone
7. Necrotising reaction in lepromatous leprosy
8. The repeatability of testing with Semmes-Weinstein monofilaments
9. 'Pocket' filaments and specifications for the Semmes-Weinstein monofilaments
10. Lymphocyte transformation test in leprosy. Correlation of the response with inflammation of the lessons
11. Plasma Factors in delayed-type hypersensitivity. Augmentation of the lymphocyte responses in borderline leprosy reactions
12. Basic nerve function assessment in leprosy patients
13. Reactional states in leprosy
14. The value of peripheral neurosurgical procedures in neuritis
15. Cyclosporin A treatment in reversal reaction
16. Protective immunity and delayed type of hypersensitivity in C57BL mice after immunisation with live Mycobacterium lepraemurium and sonicated bacilli
17. A study of autonomic functions in leprosy
18. Relapse, reactivation or reinfection
19. Pseudo exacerbation of leprosy due to diamino-diphenyl-sulfones
20. Induction of Th-1 cytokine response by mycobacterial antigens in leprosy
21. Mechanism of 'reactions' in borderline (BT) leprosy
22. Autoimmune diseases and thalidomide. II Adjuvant disease. Experimental allergic encephalitis and experimental allergic neuritis of the rat
23. The use of the voluntary muscle test in leprosy neuritis
24. Serum Neopterin as a marker for reactional states in leprosy
25. A treatment of corticosteroid-dependent lepromatous patients in persistent erythema nodosum leprosum. A clinical evaluation of G 30320 (B663)
26. Bullous type of reaction in leprosy
27. Erythema nodosum leprosum. A clinical pathological study
28. Nerve in reversal reaction
29. IL-15, an immunomodulator of T cell responses in intracellular infection
30. Chemotherapeutical trials with diffrent regimens containing rifampicin in paucibacillary type of leprosy cases - A preliminary report
31. Short term WHO-advised multiple drug treatment of paucibacillary leprosy patients
32. Nerve and skin damage in leprosy is associated with increased intralesional heat shock proteins
33. Tumour necrosis factor alpha (TNF-α) synthesis is associated with skin and peripheral nerve pathology of leprosy reversal reaction
34. In-vitro synthesis of humeral factors (immunoglobulins and complement) in lesional skin of leprosy patients
35. In-vitro synthesis of anti-mycobacterial antibodies in biopsies from skin lesions of leprosy patients
36. The 'spotted' leprosy of Lucio (la lepra 'manchada' de Lucio)
37. Clinical features and outcome of reversal (Type 1) reactions in Hyderabad, India
38. Alterations in serum lipids in lepromatous leprosy patients with and without ENL reactions and their relationship to acute phase proteins
39. Erythema nodosum leprosum
40. In-situ characterization of T lymphocyte subsets in the reactional states of leprosy
41. In-situ and in-vitro characterization of the cellular immune-response in erythema nodosum leprosum
42. Lymphokine patterns in leprosy skin lesion
43. Thymus-dependent lymphocytes in leprosy. I: T-lymphocytes subpopulations defined by monoclonal antibodies
44. Mycobacteria induce CD4+ T-cells that are cytotoxic and display Th1-like cytokine secretion profile: Heterogeneity in cytotoxic activity and cytokine secretion levels
45. Definition of a human suppressor T-cell epitope
46. A follow-up study of nerve lesions in leprosy during and after reaction, using motor nerve conduction velocity
47. Sensory testing. A sensitive method in the follow-up of nerve involvement
48. Decompression des nevrites reactionelles dans la lepre: Justification physopathologique et methodes objectives pour en apprecier les resultats
49. Reversal reaction: Prevention of permanent nerve damage. Comparison of short- and long-term steroid treatment
50. Thalidomide: Nieuwe ontwikkelingen
51. The Ellis and Ryrie tests
52. Reactions in leprosy
53. Anti-mycobacterium leprae monoclonal antibodies cross-reactive with human skin. An alternative explanation for the immune responses in leprosy
54. Leprosy reactions: New knowledge
55. Features of relapse in paucibacillary leprosy after multidrug treatment
56. Treatment of reactions and nerve damage
57. Clinical aspects of the reversal reaction
58. Nerve damage in leprosy
59. Differences in predominant phenotype and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy
60. Diffuse lepra
61. Um dos problemas na classificacao da Hanseniase.
62. Classification of leprosy
63. The recombinant 65 Kd heatshock protein of Mycobacterium bovis. Bacillus Calmette Guerin/M. tuberculosis is a major target molecule for CD4+ cytotoxic lymphocytes that lyse human monocytes
64. A review of twenty-three operations on the ulnar nerve in leprous neuritis
65. Early detection of damage to nerves in leprosy
66. Serum tumor necrosis factor and interleukin - 1 in leprosy and during lepra reactions
67. Decompression of ulnar and median nerves in leprous neuritis
68. A long term trial with clofazimine in reactive lepromatous leprosy
69. Lepra in Nederland in de periode
70. Lucio's phenomenon and immune complex deposition syndrome in lepromatous leprosy
71. Mycobacterial 65,000 MW heat-shock protein shares a carboxy-terminal epitope with human epidermal cytokeratin 1/2
72. The mycobacterial secreted antigen 85 complex possesses epitopes that are differently expressed in human leprosy lesions and Mycobacterium leprae infected armadillo tissues
73. Acute exacerbations (reactions) in leprosy
74. Lucio's phenomenon: An overview
75. Lucio's phenomenon: A comparative histologic study
76. Reactions in leprosy
77. Hypersensitivity and immune reactions and classification
78. The histopathological course of reactions in borderline leprosy and their outcome
79. The immunopathology of erythema nodosum: The role of extravascular complexes
80. Risk factors for type 1 reactions in borderline leprosy patients
81. 'Pseudo exacerbations' in 'borderline' cases
82. Lepra reaction
83. Acute ulcerative or sloughing tuberculoid leprosy
84. An appraisal of third complement component (C3) and breakdown product (C3d) in erythema nodosum leprosum (ENL)
85. Serum levels of tumor necrosis factor alpha and interleukine 1 beta during leprosy reactional states
86. Is pentoxifylline a viable alternative in the treatment of ENL?
87. The role of inflammatory cytokines in the tissue injury of leprosy
88. Use of colchicine in the management of ENL
89. Thalidomide is agonistic to the synthesis of IL-2 and it can be agonistic or antagonistic to the synthesis of TNF-α
90. Immunohistological localisation of mycobacterial antigens within the peripheral nerves of treated leprosy patients and their significance to nerve damage in leprosy
91. Pathology of nerve damage in leprosy
92. The history and future of vaccination and immunotherapy for leprosy
93. Antigen-specific supressor cells in subclinical leprosy infection
94. Steroid therapy for paralytic deformities in leprosy
95. The 'acute infiltration' reaction of lepromatous leprosy
96. Neural manifestations and differential diagnosis in leprosy
97. Immunecomplexes in leprosy patients from endemic and non-endemic areas and a longitudinal study of the relationship between complement breakdown products and the clinical activity of erythema nodosum leprosum
98. Reactions in leprosy: An epidemiological study of 386 patients in West Nepal
99. Evaluation of sensibility in leprosy - Comparison of various clinical methods
100. Similarity between mycobacteria and human epidermal antigens. A study with human sera and murine anti-M. leprae monoclonal antibodies
101. Etude comparative d'une serie de nerfs lepreux decomprimes chirurgicalement par rapport aux nerfs contralateraux non-operes
102. Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum
103. Reversal reaction in borderline leprosy is associated with a polarized shift to Type-1-like Mycobacterium leprae T-cell reactivity in lesional skin: A follow-up study
104. Type 1- and Type 2-like lesional skin derived M. leprae-responsive T-cell clones are characterized by co-expression of IFN - gamma / TNF-α and IL4/IL5/IL13 respectively
105. Immunohistological analyses of in situ expression of mycobacterial antigens in the skin lesions of leprosy patients across the histopathological spectrum
106. Tuberculoid changes in leprosy
107. Recent investigations into the sensory and neurohistological changes in leprosy
108. Effect of steroid therapy on parameters of peripheral autonomic dysfunction in leprosy patients with acute neuritis
109. Erythema nodosum in leprosy
110. Neural auto-antibodies in leprosy
111. Defining protective responses to pathogens: Cytokine profiles in leprosy lesions
112. Cytokine patterns of immunologically mediated tissue damage
113. Recent studies in acquired immunity in tuberculosis
114. Relation between delayed type hypersensitivity and immunity in tuberculosis